论文信息 - Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein - 字舞流文

Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein

M. C. Muenker | Boris Katz | O. Faye | J. Andrews | A. Iwasaki | D. Ndiaye | M. Reis | A. Ko | R. Tedder | S. Parikh | J. Ouédraogo | C. Wilen | Y. Boum | P. Cherepanov | N. Nery | F. Costa | A. Bei | A. Ring | A. Sall | C. Diagne | R. Dabiré | R. Filler | J. Shon | C. Lucas | J. Klein | Feimei Liu | A. Casanovas-Massana | M. Campbell | A. Wisnewski | I. Vigan-Womas | A. Mbengue | K. Kamath | M. Cappello | B. Diouf | Craig B. Wilen | M. Diagne | E. Baum-Jones | A. Badiane | A. Deme | A. Moore | S. Lapidus | M. Sy | D. Hodson | Myra O. McClure | M. Strine | Yile Dai | F. Somé | C. E. Moukoko | J. D. Huck | I. Ndiaye | Y. Dai | B. Sadio | K. Mangou | M. Pouye | R. Faye | Y. Mbarga | J. C. Q. Vélez | A. Srivathsan | S. Sene | B. Dièye | M. Wilson | F. Diallo | Y. Diédhiou | Amadou Moctar Mbaye | Choukri Ben-Mamoun | J. Huck | M. Campbell | Ariktha Srivathsan | A. Mbaye

[1] Cheng-Wei Cheng,et al. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models , 2022, Science Translational Medicine.

[2] Graham W. Taylor,et al. Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility , 2022, Journal of Virological Methods.

[3] A. Dicko,et al. Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[5] J. Lessler,et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020 , 2021, Emerging infectious diseases.

[6] Shuangge Ma,et al. Diverse functional autoantibodies in patients with COVID-19 , 2021, Nature.

[7] A. Dicko,et al. Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study , 2021, medRxiv.

[8] J. Scott,et al. Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[9] D. Coulibaly,et al. SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Survey among Gold Mine Workers , 2021, medRxiv.

[10] J. Scott,et al. Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya , 2021, medRxiv.

[11] Q. Ye,et al. Potential false‐positive reasons for SARS‐CoV‐2 antibody testing and its solution , 2021, Journal of medical virology.

[12] N. Kapata,et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey , 2021, The Lancet. Global health.

[13] D. Rader,et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2021, Cell.

[14] J. Scott,et al. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.

[15] A. Abimiku,et al. Cross-reactivity of two SARS-CoV-2 serological assays in a malaria-endemic setting , 2021 .

[16] A. Amoo,et al. SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers in Ibadan, Nigeria , 2020, The American journal of tropical medicine and hygiene.

[17] J. West,et al. High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa , 2020, International Journal of Infectious Diseases.

[18] J. Kempen,et al. SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia , 2020, The American journal of tropical medicine and hygiene.

[19] D. Eibach,et al. Limited specificity of commercially available SARS‐CoV‐2 IgG ELISAs in serum samples of African origin , 2020, medRxiv.

[20] D. Ekouevi,et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020 , 2020, medRxiv.

[21] E. Adams,et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi , 2020, medRxiv.

[22] A. Ko,et al. Performance of Abbott Architect, Ortho Vitros, and Euroimmun Assays in Detecting Prior SARS-CoV-2 Infection , 2020, medRxiv.

[23] Xuguang Li,et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.

[24] J. Drexler,et al. Limited Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin , 2020, Emerging infectious diseases.

[25] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[26] Daniel Wrapp,et al. Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.

[27] Shangen Zheng,et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 , 2020, Journal of Clinical Microbiology.

[28] N. Callewaert,et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[29] R. Pantazes,et al. Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology , 2020, Scientific Reports.

[30] P. Daugherty,et al. Protein-Based Immunome Wide Association Studies (PIWAS) for the Discovery of Significant Disease-Associated Antigens , 2020, bioRxiv.

[31] Samuel Tassi Yunga,et al. Measuring antibody avidity to Plasmodium falciparum merozoite antigens using a multiplex immunoassay approach , 2020, Malaria Journal.

[32] Sergei L. Kosakovsky Pond,et al. A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex , 2019, Proceedings of the National Academy of Sciences.

[33] F. Elgh,et al. Urea dilution of serum for reproducible anti-HSV1 IgG avidity index , 2019, BMC Infectious Diseases.

[34] Robert J. Pantazes,et al. Identification of disease-specific motifs in the antibody specificity repertoire via next-generation sequencing , 2016, Scientific Reports.

[35] Beatrix Ueberheide,et al. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies , 2013, The Journal of experimental medicine.

[36] V. Preedy,et al. Prospective Cohort Study , 2010 .

[37] S. Doocy,et al. Mortality after the 2003 invasion of Iraq: a cross-sectional cluster sample survey , 2006, The Lancet.

[38] M. Lappalainen,et al. Avidity of IgG in serodiagnosis of infectious diseases , 1993 .

[39] L. Lefrançois,et al. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies. , 1982, Virology.